https://www.marketscreener.com/quote/stock/BIOVERATIV-INC-33339375/news/Bioverativ-Announces-First-Patient-Dosed-in-Phase-3-Study-of-BIVV009-for-Treatment-of-Cold-Aggluti-26114104/?utm_source=telegram&utm_medium=social&utm_campaign=share